These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39080470)

  • 21. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
    Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
    Kaurinovic M; Delli K; Jonk AE; Biswana A; Hazenberg CLE; Choi G; de Groot MR; Morsink LM; Vissink A; Bellido M
    Clin Oral Investig; 2022 May; 26(5):4209-4216. PubMed ID: 35169886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three US Food and Drug Administration-approved therapies for chronic GVHD.
    Zeiser R; Lee SJ
    Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.
    Olivieri A; Mancini G
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
    Wolff D; Hilgendorf I; Wagner-Drouet E; Jedlickova Z; Ayuk F; Zeiser R; Schäfer-Eckart K; Gerbitz A; Stadler M; Klein S; Middeke JM; Lawitschka A; Winkler J; Halter J; Holler E; Kobbe G; Stelljes M; Ditschkowski M; Greinix H
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1450-1455. PubMed ID: 30876928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Jeppesen H; Gjærde LK; Lindegaard J; Julian HO; Heegaard S; Sengeløv H
    Transplant Cell Ther; 2022 Dec; 28(12):833.e1-833.e7. PubMed ID: 36002105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
    Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
    Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
    Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
    Gagliardi TA; Milner J; Cairo MS; Steinberg A
    Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Rahmat LT; Logan AC
    Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
    Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
    Front Immunol; 2020; 11():578314. PubMed ID: 33162993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.
    Shi CR; Ferreira AL; Kaur M; Xiang D; Caputo J; Choe HK; Hamad N; Cowen EW; Kaffenberger BH; Baumrin E
    Transplant Cell Ther; 2024 Sep; 30(9S):S513-S533. PubMed ID: 39370234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.
    Buder K; Zirngibl M; Bapistella S; Meerpohl JJ; Strahm B; Bassler D; Weitz M
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009898. PubMed ID: 35679154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral Complications of Chronic Graft-Versus-Host Disease.
    Fall-Dickson JM; Pavletic SZ; Mays JW; Schubert MM
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.